Increased Synthesis of Prostaglandin-E-like Material by Platelets from Patients with Diabetes Mellitus

New England Journal of Medicine

Volumn 297, Issue 24, 1977, Pages 1306-1310

  Halushka, Perry V ^a   Lurie, Dan ^a   Colwell, John A ^a  

^a Veterans Administration Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; COLLAGEN; PROSTAGLANDIN E; PROSTAGLANDIN E2 H 3; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; MAJOR CLINICAL STUDY; PROSTAGLANDIN SYNTHESIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE METABOLISM;

EID: 0017670979     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197712152972402     Document Type: Article

References (33)

1. Heath H, Brigden WD, Canever JV, et al: Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 7: 308–315, 1971
2. Bensoussan D, Levy-Toledano S, Passa P, et al: Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia 11: 307–312, 1975
3. O'Malley BC, Timperly WR, Ward JD, et al: Platelet abnormalities in diabetic peripheral neuropathy. Lancet 2: 1274–1276, 1975
4. Leone G, Bizzi B, Accorrà F, et al: Functional aspect of platelets in diabetes mellitus, Platelet Aggregation and Drugs. Edited by L Caprino, EC Rossi. New York, Academic Press, 1974, pp 49–61
5. Sagel J, Colwell JA, Crook L, et al: Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 82: 733–738, 1975
6. Kwaan HC, Colwell JA, Cruz S, et al: Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 80: 236–246, 1972
7. Smith JB, Ingerman C, Kocsis JJ, et al: Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction. J Clin Invest 53: 1468–1472, 1974
8. Willis AL, Vane FM, Kuhn DC, et al: An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance. Prostaglandins 8: 453–491, 1974
9. Hamberg M, Samuelsson B: Prostaglandin endoperoxides: novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 71: 3400–3404, 1974
10. Hamberg M, Svensson J, Samuelsson B: Prostaglandin endoperoxides: a new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci USA 71: 3824–3828, 1974
11. Hamberg M, Svensson J, Wakabayashi T, et al: Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 71: 345–349, 1974
12. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994–2998, 1975
13. Smith JB, Ingerman C, Silver MJ: Persistence of thromboxane A2-like material and platelet release-inducing activity in plasma. J Clin Invest 58: 1119–1122, 1976
14. Smith JB, Willis AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nature [New Biol] 231: 235–237, 1971
15. Silver MJ, Smith JB, Ingerman C, et al: Human blood prostaglandins: formation during clotting. Prostaglandins 1: 429–436, 1972
16. Smith JB, Ingerman C, Kocsis JJ, et al: Formation of prostaglandins during the aggregation of human blood platelets. J Clin Invest 52: 965–969, 1973
17. Malmsten C, Hamberg M, Svensson J, et al: Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclooxygenase deficiency. Proc Natl Acad Sci USA 72: 1446–1450, 1975
18. Colwell JA, Chambers A, Laimins M: Inhibition of labile aggregationstimulating substance (LASS) and platelet aggregation in diabetes mellitus. Diabetes 24: 684–687, 1975
19. Mustard JF, Packham MA: Factors influencing platelet function: adhesion, release, and aggregation. Pharmacol Rev 22: 97–187, 1970
20. Tschopp TB, Zucker MB: Platelet function tests in disease. Annu Rev Med 24: 1–18, 1973
21. Fajans SS, Conn JW: An approach to prediction of diabetes mellitus by modification of glucose tolerance test with cortisone. Diabetes 3: 296–304, 1954
22. Alexander RW, Kent KM, Pisano JJ, et al: Regulation of postocclusive hyperemia by endogenously synthesized prostaglandins in the dog heart. J Clin Invest 55: 1174–1181, 1975
23. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927–929, 1962
24. Steel RGD, Torrie JH: Principles and Procedures of Statistics. New York, McGraw-Hill, 1960
25. Colwell JA, Halushka PV, Sarji K, et al: Altered platelet function in diabetes mellitus. Diabetes 25: Suppl 2: 826–831, 1976
26. Ferguson JC, Mackay N, Philip JAD, et al: Determination of platelet and fibrinogen half-life with [75SE]selenomethionine: studies in normal and in diabetic subjects. Clin Sci Mol Med 49: 115–120, 1975
27. Garg SK, Lackner H, Karpatkin S: The increased percentage of megathrombocytes in various clinical disorders. Ann Intern Med 77: 361–369, 1972
28. Colwell JA, Sagel J, Crook L, et al: Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with and without vascular disease. Metabolism 26: 279–285, 1976
29. Karpatkin S: Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 48: 1073–1082, 1969
30. Karpatkin: Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 48: 1083–1087, 1969
31. Tannenbaum J, Nies AS, Aulsebrook K, et al: Release of prostaglandins from rat renal papilla in vitro: effect of glucose concentration. Fed Proc 35: 223, 1976
32. Van Pragg D, Farber SJ: Effect of increased osmolality on prostaglandin metabolism in rabbit kidney. Fed Proc 35: 223, 1976
33. Powell EDU, Field RA: Diabetic retinopathy and rheumatoid arthritis. Lancet 2: 17–18, 1964